US4722848A
(en)
|
1982-12-08 |
1988-02-02 |
Health Research, Incorporated |
Method for immunizing animals with synthetically modified vaccinia virus
|
WO1988007089A1
(fr)
|
1987-03-18 |
1988-09-22 |
Medical Research Council |
Anticorps alteres
|
US5391481A
(en)
|
1990-08-31 |
1995-02-21 |
The Trustees Of Columbia University |
Antibody which is directed against and inhibits collagen binding to a VLA-1 epitope and uses thereof
|
GB9022040D0
(en)
|
1990-10-10 |
1990-11-21 |
Biopharm Ltd |
Platelet adhesion inhibitor
|
US5851794A
(en)
|
1990-10-22 |
1998-12-22 |
Alfa Laval Ab |
Collagen binding protein as well as its preparation
|
US5173414A
(en)
|
1990-10-30 |
1992-12-22 |
Applied Immune Sciences, Inc. |
Production of recombinant adeno-associated virus vectors
|
CA2117780A1
(fr)
|
1992-04-10 |
1993-10-28 |
Paul F. Goetinck |
Proteine structurale de cartilage et modes d'emploi
|
US5491130A
(en)
|
1992-11-10 |
1996-02-13 |
The United States Of America As Represented By The Department Of Health And Human Services |
Peptide inhibitors of fibronectin and related collagen-binding proteins
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
US5849589A
(en)
|
1996-03-11 |
1998-12-15 |
Duke University |
Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
|
EP0950068B1
(fr)
|
1996-05-16 |
2005-11-09 |
THE TEXAS A&M UNIVERSITY SYSTEM |
Compositions de proteine de liaison du collagene et procedes d'utilisation
|
US7951917B1
(en)
|
1997-05-02 |
2011-05-31 |
Genentech, Inc. |
Method for making multispecific antibodies having heteromultimeric and common components
|
WO1999029732A2
(fr)
|
1997-12-08 |
1999-06-17 |
Lexigen Pharmaceuticals Corporation |
Proteines de fusion heterodymeres utiles en therapie immune ciblee et a une stimulation immune generale
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
US6387663B1
(en)
|
1998-07-31 |
2002-05-14 |
University Of Southern California |
Targeting pharmaceutical agents to injured tissues
|
WO2000021989A1
(fr)
|
1998-10-09 |
2000-04-20 |
Medimmune, Inc. |
Proteines dbp a et b liant la decorine et gene codant pour elles
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
US7183387B1
(en)
|
1999-01-15 |
2007-02-27 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
US6566489B1
(en)
|
1999-03-15 |
2003-05-20 |
The General Hospital Corporation |
Syndecan-4 binding protein (S4BP) and uses thereof
|
US6864235B1
(en)
|
1999-04-01 |
2005-03-08 |
Eva A. Turley |
Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
|
US6908994B1
(en)
|
1999-05-10 |
2005-06-21 |
The Texas A&M University System |
Collagen-binding proteins from enterococcal bacteria
|
AU5495500A
(en)
|
1999-06-16 |
2001-01-02 |
The Texas A & M University System |
Decorin binding protein essential peptides and methods of use
|
AU5622800A
(en)
|
1999-06-18 |
2001-01-09 |
Med Immune, Inc. |
Combined decorin binding protein and outer surface protein compositions and methods of use
|
CA2394576A1
(fr)
|
1999-12-15 |
2001-06-21 |
Research Development Foundation |
Betaglycane utilise comme recepteur de l'inhibine et ses utilisations
|
US6777547B1
(en)
|
2000-01-31 |
2004-08-17 |
Andreas Podbielski |
Collagen-binding proteins from streptococcus pyogenes
|
US6517838B1
(en)
|
2000-06-16 |
2003-02-11 |
The Texas A&M University System |
Decorin binding protein essential peptides and methods of use
|
WO2002024223A2
(fr)
|
2000-09-21 |
2002-03-28 |
The Brigham And Women's Hospital, Inc. |
Prevention et traitement d'une infection streptococcique et staphylococcique
|
JP4281869B2
(ja)
|
2001-06-22 |
2009-06-17 |
中外製薬株式会社 |
抗グリピカン3抗体を含む細胞増殖抑制剤
|
US8192744B2
(en)
|
2002-08-26 |
2012-06-05 |
Ibcc Holding As |
Drug for treating states related to the inhibition of angiogenesis and/or endothelial cell proliferation
|
US7488792B2
(en)
|
2002-08-28 |
2009-02-10 |
Burnham Institute For Medical Research |
Collagen-binding molecules that selectively home to tumor vasculature and methods of using same
|
GB0406415D0
(en)
|
2004-03-22 |
2004-04-21 |
Inst Of Cancer Res The |
Materials and methods for treatment of cancer
|
WO2005114186A1
(fr)
|
2004-05-20 |
2005-12-01 |
Wako Pure Chemical Industries, Ltd. |
Procédé de dosage de l'acide hyaluronique en utilisant une protéine liant l'acide hyaluronique
|
WO2005124356A2
(fr)
|
2004-06-18 |
2005-12-29 |
Roche Diagnostics Gmbh |
Utilisation d'une proteine cbp2 en tant que marqueur pour un cancer colorectal
|
NZ579543A
(en)
|
2004-07-09 |
2011-07-29 |
Chugai Pharmaceutical Co Ltd |
Anti-glypican 3 antibody
|
US7820401B2
(en)
|
2004-08-23 |
2010-10-26 |
Albert Einstein College Of Medicine Of Yeshiva University |
Collagen VI and cancer
|
US20090142345A1
(en)
|
2005-03-15 |
2009-06-04 |
Takeda Pharmaceutical Company Limited |
Prophylactic/therapeutic agent for cancer
|
JP5140579B2
(ja)
|
2005-06-08 |
2013-02-06 |
カンジェーン コーポレイション |
病原菌に対する生体防御を増強するヒアルロン酸結合性ペプチド
|
CN104356236B
(zh)
|
2005-07-01 |
2020-07-03 |
E.R.施贵宝&圣斯有限责任公司 |
抗程序性死亡配体1(pd-l1)的人单克隆抗体
|
EP1999154B1
(fr)
|
2006-03-24 |
2012-10-24 |
Merck Patent GmbH |
Domaines de proteine heterodimerique d'ingenierie
|
EP1864996A1
(fr)
|
2006-06-06 |
2007-12-12 |
Helmholtz-Zentrum für Infektionsforschung GmbH |
Peptide associé de la fievre rhumatismale et son utilisation comme marquer diagnostique.
|
HU0600578D0
(en)
|
2006-07-13 |
2006-09-28 |
Szilak Labor Bioinformatikai E |
Nuclear protein transport
|
CA2660455A1
(fr)
|
2006-08-08 |
2008-02-14 |
Seikagaku Corporation |
Procede de determination du poids moleculaire d'un acide hyaluronique
|
WO2008089448A2
(fr)
|
2007-01-19 |
2008-07-24 |
Cornell Presearch Foundation, Inc. |
Procédés et compositions pour la favorisation de la survie et de la prolifération de cellules endothéliales et la stimulation d'angiogenèse
|
US8680247B2
(en)
|
2007-07-17 |
2014-03-25 |
Medarex, L.L.C. |
Monoclonal antibodies against glypican-3
|
WO2009089004A1
(fr)
|
2008-01-07 |
2009-07-16 |
Amgen Inc. |
Méthode de fabrication de molécules hétérodimères fc d'anticorps utilisant les effets de conduite électrostatique
|
US8663929B2
(en)
|
2008-03-17 |
2014-03-04 |
University Of Miyazaki |
Method for detection of liver cancer cell using anti-glypican-3 antibody
|
US20090297479A1
(en)
|
2008-03-28 |
2009-12-03 |
Kiyoshi Ariizumi |
Dc-hil conjugates for treatment of t-cell disorders
|
CA2720368C
(fr)
|
2008-04-02 |
2017-08-22 |
Macrogenics, Inc. |
Anticorps specifiques de her2/neu et procedes d'utilisation de ceux-ci
|
JP5477287B2
(ja)
|
2008-04-15 |
2014-04-23 |
和光純薬工業株式会社 |
新規なヒアルロン酸結合能を有するタンパク質及びこれを用いたヒアルロン酸の測定方法
|
WO2010033866A2
(fr)
|
2008-09-19 |
2010-03-25 |
University Of Pittsburgh-Of The Commonwealth System Of Higher Education |
Anticorps monoclonaux de cspg4 utilises dans le diagnostic et le traitement du carcinome mammaire de type basal
|
GB0818273D0
(en)
|
2008-10-06 |
2008-11-12 |
Cambridge Entpr Ltd |
Modulation of cellular activity and differentiation
|
KR101105428B1
(ko)
|
2009-02-12 |
2012-01-17 |
경북대학교 산학협력단 |
글리피칸-3 단백질과 특이적으로 결합하는 펩타이드
|
EP2417159A1
(fr)
|
2009-04-07 |
2012-02-15 |
Roche Glycart AG |
Anticorps anti-erbb-3/anti-c-met bispécifiques
|
US20120100106A1
(en)
|
2009-05-04 |
2012-04-26 |
Purdue Research Foundation |
Collagen-binding synthetic peptidoglycans for wound healing
|
JP5764127B2
(ja)
|
2009-08-17 |
2015-08-12 |
ロシュ グリクアート アーゲー |
標的化イムノコンジュゲート
|
US9493578B2
(en)
|
2009-09-02 |
2016-11-15 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
SG184427A1
(en)
*
|
2010-04-20 |
2012-11-29 |
Genmab As |
Heterodimeric antibody fc-containing proteins and methods for production thereof
|
RU2624027C2
(ru)
|
2010-04-23 |
2017-06-30 |
Дженентек, Инк. |
Получение гетеромультимерных белков
|
CN103068846B9
(zh)
|
2010-08-24 |
2016-09-28 |
弗·哈夫曼-拉罗切有限公司 |
包含二硫键稳定性Fv片段的双特异性抗体
|
WO2012032080A1
(fr)
|
2010-09-07 |
2012-03-15 |
F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H |
Fc humain stabilisé
|
US8906649B2
(en)
|
2010-09-27 |
2014-12-09 |
Janssen Biotech, Inc. |
Antibodies binding human collagen II
|
JP6167040B2
(ja)
|
2010-11-05 |
2017-07-19 |
ザイムワークス,インコーポレイテッド |
Fcドメイン中に突然変異を有する、安定したヘテロ二量体抗体の設計
|
JP6100694B2
(ja)
|
2010-11-15 |
2017-03-22 |
ピエリス ファーマシューティカルズ ゲーエムベーハー |
グリピカン−3(gpc3)に対して親和性を有するヒトリポカリン2の突然変異タンパク質
|
BR112013013311A2
(pt)
*
|
2010-11-30 |
2017-09-19 |
Chugai Pharmaceutical Co Ltd |
agente terapêutico de indução de citotoxicidade
|
US10689447B2
(en)
|
2011-02-04 |
2020-06-23 |
Genentech, Inc. |
Fc variants and methods for their production
|
DK3489255T3
(da)
*
|
2011-02-10 |
2021-08-23 |
Roche Glycart Ag |
Muterede interleukin-2-polypeptider
|
EP3590965A1
(fr)
|
2011-03-29 |
2020-01-08 |
Roche Glycart AG |
Variants de fc d'anticorps
|
EP3070104B1
(fr)
|
2011-04-19 |
2017-12-27 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Anticorps monoclonaux humains spécifiques au glypican-3 et leur utilisation
|
EA201892619A1
(ru)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
ES2708076T3
(es)
|
2011-05-24 |
2019-04-08 |
Symic Ip Llc |
Peptidoglicanos sintéticos que se unen al ácido hialurónico, preparación y métodos de uso
|
PL3351261T3
(pl)
*
|
2011-10-11 |
2021-12-06 |
Universität Zürich |
Lek złożony zawierający IL-12 i środek do blokowania cząsteczek hamujących komórki T w terapii nowotworów
|
US20140322216A1
(en)
|
2011-11-08 |
2014-10-30 |
The Trustees Of The University Of Pennsylvania |
Glypican-3-specific antibody and uses thereof
|
EP2804586A4
(fr)
|
2012-01-19 |
2016-03-16 |
Univ Johns Hopkins |
Biomatériaux comprenant des peptides se liant à l'acide hyaluronique et des molécules biopolymères bifonctionnelles pour des applications de rétention d'acide hyaluronique et d'ingénierie tissulaire
|
NZ630551A
(en)
|
2012-04-20 |
2017-11-24 |
Merus Nv |
Methods and means for the production of ig-like molecules
|
WO2013163766A1
(fr)
|
2012-05-04 |
2013-11-07 |
Cangene Corporation |
Compositions antimicrobiennes comprenant un peptide de liaison à l'acide hyaluronique et un antibiotique β-lactame
|
WO2013174783A1
(fr)
|
2012-05-23 |
2013-11-28 |
Pieris Ag |
Mutéines de lipocaline avec affinité de liaison pour le glypican-3 (gpc-3) et utilisation de mutéines de lipocaline pour la délivrance spécifique de la cible aux cellules exprimant le gpc-3
|
JP6494507B2
(ja)
|
2012-06-01 |
2019-04-03 |
ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
グリピカン−3に対する高親和性モノクローナル抗体およびその使用
|
DK2880170T3
(en)
|
2012-08-02 |
2016-10-24 |
Hoffmann La Roche |
PROCEDURE FOR PREPARING SOLUBLE FcR AS Fc FUSION WITH INERT IMMUNOGLOBULIN Fc REGION AND APPLICATIONS THEREOF
|
SG11201408530YA
(en)
|
2012-08-02 |
2015-03-30 |
Hoffmann La Roche |
Method for producing monomeric and multimeric molecules and uses thereof
|
MX365382B
(es)
|
2012-08-07 |
2019-05-31 |
Roche Glycart Ag |
Una combinación de inmunoconjugado y anticuerpo para usarse en el tratamiento de cáncer.
|
US9951145B2
(en)
|
2012-11-27 |
2018-04-24 |
Ajou University Industry—Academic Cooperation Foundation |
CH3 domain variant pair inducing formation of heterodimer of heavy chain constant region of antibody at high efficiency, method for preparing same, and use thereof
|
US20140302037A1
(en)
*
|
2013-03-15 |
2014-10-09 |
Amgen Inc. |
BISPECIFIC-Fc MOLECULES
|
SG11201507429TA
(en)
*
|
2013-03-15 |
2015-10-29 |
Genentech Inc |
Il-22 polypeptides and il-22 fc fusion proteins and methods of use
|
AU2014232416B2
(en)
|
2013-03-15 |
2017-09-28 |
Xencor, Inc. |
Modulation of T Cells with Bispecific Antibodies and FC Fusions
|
US10047167B2
(en)
|
2013-03-15 |
2018-08-14 |
Eli Lilly And Company |
Methods for producing fabs and bi-specific antibodies
|
EP2992010B1
(fr)
|
2013-04-29 |
2021-03-24 |
F.Hoffmann-La Roche Ag |
Anticorps asymétrique modifié de liaison fc-receptor et procédés d'utilisation
|
US10093745B2
(en)
|
2013-05-29 |
2018-10-09 |
The Regents Of The University Of California |
Anti-CSPG4 fusions with interferon for the treatment of malignancy
|
AR096891A1
(es)
|
2013-07-12 |
2016-02-03 |
Hanmi Pharm Ind Co Ltd |
Conjugado de monómero polipéptido biológicamente activo y conjugado de fragmento fc de inmunoglobulina, que muestra aclaramiento mediado por receptor reducido, y el método para la preparación del mismo
|
UA117289C2
(uk)
|
2014-04-02 |
2018-07-10 |
Ф. Хоффманн-Ля Рош Аг |
Мультиспецифічне антитіло
|
US20160032007A1
(en)
|
2014-04-28 |
2016-02-04 |
Duke University |
Human Antibody Fragments Against Chondroitin Sulfate Proteoglycan 4 (CSPG4)
|
BR122021009041B1
(pt)
|
2014-05-06 |
2022-11-29 |
Genentech, Inc |
Métodos para a preparação de uma proteína heteromultimérica
|
CA2952727A1
(fr)
|
2014-06-27 |
2015-12-30 |
Innate Pharma |
Proteines de liaison nkp46 multispecifiques
|
WO2016007919A2
(fr)
|
2014-07-11 |
2016-01-14 |
Regents Of The University Of Minnesota |
Fragments d'anticorps pour détecter un cancer et méthodes d'utilisation
|
MA40764A
(fr)
|
2014-09-26 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Agent thérapeutique induisant une cytotoxicité
|
RU2713131C1
(ru)
|
2014-11-06 |
2020-02-03 |
Ф. Хоффманн-Ля Рош Аг |
ВАРИАНТЫ Fc-ОБЛАСТИ С МОДИФИЦИРОВАННЫМИ СВОЙСТВАМИ СВЯЗЫВАНИЯ FcRn И БЕЛКА А
|
SI3215528T1
(sl)
|
2014-11-06 |
2019-11-29 |
Hoffmann La Roche |
Variante regije Fc s spremenjeno vezavo FcRn in postopki uporabe
|
CA2967350C
(fr)
|
2014-11-12 |
2021-11-23 |
The General Hospital Corporation |
Anticorps anti-proteoglycane de chondroitine-sulfate 4 et utilisations de ceux-ci
|
WO2016154019A1
(fr)
|
2015-03-20 |
2016-09-29 |
Orbsen Therapeutics Limited |
Modulateurs de de syndécane 2 et leurs utilisations
|
US10881711B2
(en)
|
2015-04-06 |
2021-01-05 |
The General Hospital Corporation |
Anti-CSPG4 reagents and methods of treating cancer
|
WO2016208754A1
(fr)
|
2015-06-24 |
2016-12-29 |
学校法人慶應義塾 |
Récepteur antigénique immunisant anti-glypicane-1
|
RU2740672C2
(ru)
*
|
2015-08-07 |
2021-01-19 |
ЭйЭлЭкс Онколоджи Инк. |
Конструкции, имеющие sirp-альфа домен или его вариант
|
AU2016322919B2
(en)
|
2015-09-14 |
2022-12-22 |
Regents Of The University Of Minnesota |
NK cells exhibiting an adaptive phenotype and methods for preparing and for using
|
ES2809125T3
(es)
|
2015-09-23 |
2021-03-03 |
Bristol Myers Squibb Co |
Moléculas de armazón a base de fibronectina de unión a glipicano-3
|
WO2017062604A1
(fr)
|
2015-10-06 |
2017-04-13 |
Regents Of The University Of Minnesota |
Composés thérapeutiques et procédés
|
KR101851380B1
(ko)
|
2015-10-12 |
2018-04-23 |
아주대학교산학협력단 |
효모접합을 이용한 항체 ch3 도메인 이종이중체 돌연변이쌍 제조 방법 및 이에 의하여 제조된 ch3 돌연변이체 쌍
|
KR101796688B1
(ko)
|
2015-10-29 |
2017-12-01 |
재단법인 목암생명과학연구소 |
신규 항-글리피칸 3 항체 및 이를 포함하는 약학적 조성물
|
JP6983824B2
(ja)
|
2016-07-04 |
2021-12-17 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
新規抗体フォーマット
|
AU2017305170A1
(en)
|
2016-08-02 |
2019-02-14 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies targeting glypican-2 (GPC2) and use thereof
|
WO2018030806A1
(fr)
*
|
2016-08-10 |
2018-02-15 |
아주대학교산학협력단 |
Cytokine fusionnée à un hétérodimère fc d'immunoglobuline et composition pharmaceutique la contenant
|
CA3033475A1
(fr)
|
2016-08-10 |
2018-02-15 |
Ajou University Industry-Academic Cooperation Foundation |
Cytokine a fusion fc heterodimerique et composition pharmaceutique la comprenant
|
CN110214148A
(zh)
*
|
2016-10-14 |
2019-09-06 |
Xencor股份有限公司 |
含有IL-15/IL-15Rα Fc融合蛋白和PD-1抗体片段的双特异性异源二聚体融合蛋白
|
CA3054079A1
(fr)
|
2017-02-20 |
2018-08-23 |
Dragonfly Therapeutics, Inc. |
Proteines se liant a her2, nkg2d et cd16
|
CN110831634A
(zh)
|
2017-03-08 |
2020-02-21 |
密歇根大学董事会 |
磷脂酰肌醇蛋白聚糖-3肽试剂和方法
|
RU2019133202A
(ru)
|
2017-03-27 |
2021-04-28 |
Ф. Хоффманн-Ля Рош Аг |
Улучшенные антигенсвязывающие рецепторы
|
US11242403B2
(en)
|
2017-04-26 |
2022-02-08 |
Mitsubishi Tanabe Pharma Corporation |
Syndecan-1 (CD138) binding agents and uses thereof
|
WO2018199318A1
(fr)
|
2017-04-28 |
2018-11-01 |
国立大学法人高知大学 |
Anticorps anti-gpc-1
|
JP2019014449A
(ja)
|
2017-07-10 |
2019-01-31 |
トヨタ自動車株式会社 |
車両用動力伝達装置
|
CA3112984A1
(fr)
|
2017-09-07 |
2019-03-14 |
Dragonfly Therapeutics, Inc. |
Proteines de liaison a nkg2d, cd16 et un antigene associe a une tumeur
|
EP3684791A1
(fr)
*
|
2017-09-21 |
2020-07-29 |
Merck Patent GmbH |
Protéine de fusion comprenant une fraction fgf-18
|
BR112020005676A2
(pt)
*
|
2017-09-22 |
2020-10-20 |
WuXi Biologics Ireland Limited |
novos complexos polipeptídicos biespecíficos
|
CN111246885A
(zh)
|
2017-10-20 |
2020-06-05 |
豪夫迈·罗氏有限公司 |
从单特异性抗体生成多特异性抗体的方法
|
AU2019218125A1
(en)
|
2018-02-08 |
2020-08-20 |
Dragonfly Therapeutics, Inc. |
Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells
|
DE102018208278A1
(de)
|
2018-05-25 |
2019-11-28 |
Robert Bosch Gmbh |
Betriebsassistenzverfahren, Steuereinheit, Betriebsassistenzsystem und Arbeitsvorrichtung
|
MX2021000287A
(es)
*
|
2018-07-11 |
2021-09-08 |
Momenta Pharmaceuticals Inc |
Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc modificados genéticamente.
|
PE20211279A1
(es)
|
2018-10-23 |
2021-07-19 |
Dragonfly Therapeutics Inc |
Proteinas heterodimericas fusionadas con fc
|